Migraines: sales of triptans to double by 2007

Published By Datamonitor

Merck/NicOx: more reinvention rather than innovation

Big pharma, in the shape of Merck & Co, has once again dipped its hand into the biopharma goody bag to bolster R&D pipelines. The deal, potentially worth around $350 million to NicOx, comes only days after NicOx inked a similar sized deal with Pfizer in ophthalmology, and should help boost Merck's lifecycle management efforts.

Published By Datamonitor

Johnson & Johnson: can canagliflozin do what dapa didn't?

New clinical trial data for canagliflozin have revealed that its blood glucose-lowering abilities show superiority to blockbuster gold-standard Januvia, with the added benefit of weight loss. The potential for first-to-market SGLT-2 inhibitor status in the US and its good safety and efficacy profile boost canagliflozin's chances for success in a crowded diabetes market.

Published By Datamonitor

Insys Therapeutics: first-to-market sublingual fentanyl spray to enter a highly competitive space

Insys Therapeutics' Subsys represents the first oral spray formulation to gain US approval for the treatment of breakthrough cancer pain. The drug's rapid onset of analgesic action and ease of administration offer distinct clinical benefits to patients. However, Subsys will face strong competition from generic Actiq and other rapidly acting fentanyl brands upon launch.

Published By Datamonitor

Influenza: pipeline products worth $0.5 billion by 2007

Published By Datamonitor

Hypercholesterolemia: Japanese cases to grow 16% by 2005

Published By Datamonitor

HIV/AIDS: US diagnosis 'average' in top seven markets

Published By Datamonitor

HIV market: set to undergo dramatic changes over next decade

Published By Datamonitor

Hepatitis immunization: study slams French policy

The French government has come under severe criticism for its failure to effectively monitor the safety of hepatitis B immunization programs. Since maintaining public confidence in immunization programs is vital to both national health and vaccine profitability, other governments should learn from France's mistakes.

Published By Datamonitor

GlaxoSmithKline: a hearty triumph for Arixtra

GlaxoSmithKline looks set to enhance its thrombosis market position after study results suggested Arixtra could become the treatment of choice in acute coronary syndrome. In the study Arixtra demonstrated equivalent efficacy to Sanofi-Aventis' Lovenox but with significantly less bleeding. These results are a clear fillip for GSK, from which a considerable marketing push for Arixtra is expected.

Published By Datamonitor